Published online before print June 23, 2008, doi: 10.1161/HYPERTENSIONAHA.108.115006
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2008;52:402.)
© 2008 American Heart Association, Inc.
Original Articles |
Nitric Oxide Formation Is Inversely Related to Serum Levels of Antiangiogenic Factors Soluble Fms-Like Tyrosine Kinase-1 and Soluble Endogline in Preeclampsia
From the Departments of Pharmacology (V.C.S., I.F.M., J.E.T-S.) and Gynecology and Obstetrics (R.C.C.), Faculty of Medicine of Ribeirao Preto, and Department of Pharmacology (A.C.T.P, V.A.G.), Faculty of Medical Sciences, State University of Campinas, Sao Paulo, Brazil.
Correspondence to Jose E. Tanus-Santos, Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Av Bandeirantes, 3900, 14049-900 Ribeirao Preto, Sao Paulo, Brazil. E-mail tanus{at}fmrp.usp.br
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Deficient NO formation has been implicated in hypertensive disorders of pregnancy. However, no previous study has compared the circulating nitrite concentrations in healthy pregnant women with those found in hypertensive disorders of pregnancy. Moreover, 2 antiangiogenic factors produced in the placenta (soluble fms-like tyrosine kinase-1 and soluble endogline) may affect NO formation during pregnancy. Here, we hypothesized that lower concentrations of markers of NO formation exist in hypertensive disorders of pregnancy and that inverse relationships exist between these markers and soluble fms-like tyrosine kinase-1 or soluble endogline. In this cross-sectional study, we compared 58 healthy pregnant women with 56 gestational hypertensive subjects and 45 preeclamptic patients. We measured plasma and whole blood nitrite concentrations using an ozone-based chemiluminescence assay and serum soluble fms-like tyrosine kinase-1 and soluble endogline concentrations using enzyme immunoassays. Whole blood nitrite levels were significantly lower in gestational hypertensive subjects and preeclamptic patients (–36% and –58%, respectively; both P<0.05) compared with healthy pregnant women. The plasma nitrite levels were
37% lower in both groups with hypertensive disorders of pregnancy compared with the group with normotensive pregnancies (both P<0.05). As expected, we found higher circulating soluble fms-like tyrosine kinase-1 and soluble endogline concentrations in preeclampsia compared with gestational hypertensive subjects or with healthy pregnancies (both P<0.05). We found negative correlations between antiangiogenic factors and plasma or whole blood nitrite concentrations (Spearman’s r from –0.175 to –0.226; all P<0.05). Our results show clinical evidence for impaired NO formation in preeclampsia or gestational hypertension. The negative correlations between markers of NO formation and antiangiogenic factors in preeclamptic patients suggest an inhibitory effect for these factors on NO formation.
Key Words: NO • nitrite • whole blood nitrite • preeclampsia • sEng • sFLT-1
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Normal human pregnancy is accompanied by increased blood volume that is accommodated within the cardiovascular system by systemic vasodilatation.1 This vasodilatation involves increased NO formation, thus decreasing peripheral vascular resistance in healthy pregnant women.2,3 On the other hand, deficient NO formation has been implicated in hypertensive disorders of pregnancy, such as preeclampsia and gestational hypertension.4–7 Indeed, previous studies compared the circulating concentrations of NO metabolites (nitrite+nitrate) in the plasma from preeclamptic women with those found in healthy pregnant women.8–13 Conflicting results were reported, and some studies showed higher,14 similar,10,12 or lower8 nitrite+nitrate levels in preeclamptic women compared with healthy pregnant women. A possible explanation for these discrepancies is that nitrite+nitrate may not accurately reflect endogenous NO formation in vivo, and there is mounting evidence that measuring the circulating concentrations of nitrite is an improved alternative to assess endogenously produced NO.15–19 However, no previous study has compared the circulating nitrite concentrations in healthy pregnant women with those found in women with preeclampsia.
The pathophysiology of preeclampsia is not completely known. However, there is evidence that a failure of cytotrophoblast invasion and absence of dilatation of uterine arteries lead to a high-resistance uteroplacental circulation, thus reducing placental perfusion and causing hypoxia, which, in turn, induces the release of factors to the maternal circulation that causes systemic endothelial dysfunction.20–22 Two important antiangiogenic factors produced in the placenta gain access to the maternal circulation and are involved in the pathogenesis of preeclampsia.23–25 First, soluble fms-like tyrosine kinase-1 (sFLT-1) is a splice variant of the vascular endothelial growth factor receptor that captures vascular endothelial growth factor,26,27 thus preventing its interaction with ligands and downregulating the biological effects of vascular endothelial growth factor, such as angiogenesis28 and stimulation of NO synthesis by endothelial cells.29–31 Second, although soluble endogline (sEng) is found in healthy pregnancies, its concentrations increase in preeclampsia. This is relevant because sEng is a transforming growth factor (TGF)-β1 and -β3 coreceptor that is highly expressed in vascular endothelial cells32 and may inhibit TGF-β1 signaling in the vasculature.33,34 Interestingly, endoglin modulates endothelial NO synthase (eNOS) expression and activity, thus affecting vascular tone.35–37
In the present study, we hypothesized that lower concentrations of relevant markers of NO formation (plasma and whole blood nitrite) would be found in hypertensive disorders of pregnancy compared with those found in healthy pregnancies. In addition, given the fact that sFLT-1 and sEng interfere with eNOS activity, we hypothesized that inverse relationships exist between the circulating concentrations of markers of NO formation and sFLT-1 or sEng during pregnancy.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Subjects
Approval for the use of human subjects was obtained from the institutional review board at the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, and subjects gave informed consent. The procedures followed were in accordance with institutional guidelines. A total of 159 pregnant were enrolled in the University Hospital of the Faculty of Medicine of Ribeirao Preto Department of Obstetrics and Gynecology. Of these, 58 were healthy pregnant women with uncomplicated pregnancies, 56 were gestational hypertensive subjects, and 45 had preeclampsia. Hypertensive disorders were defined in accordance with the guidelines of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy.38 Gestational hypertension was defined as pregnancy-induced hypertension (
140 mm Hg systolic or 90 mm Hg diastolic on 2 measurements 6 hours apart) without significant proteinuria in a woman after 20 weeks of gestation and returning to normal by 12 weeks postpartum. Preeclampsia was defined as increased blood pressure with significant proteinuria (0.3 g/24 hours) in a woman after 20 weeks of gestation. No women with preexisting hypertension, with or without superimposed preeclampsia, were included in the present study. Exclusion criteria included twin or multiple pregnancies or any evidence of previous medical illness. At the time of clinic attendance, maternal venous blood samples were collected into standard Vacutainer tubes (Becton-Dickinson) containing heparin or clot activator (serum). The tubes were immediately centrifuged at 1000g for 3 minutes at room temperature, and plasma/serum samples were stored at –70°C until used to measure plasma nitrite and serum sFLT-1 and sEng concentrations. An aliquot of whole blood was mixed with a nitrite preservation solution in a 4:1 dilution, as described previously,39–41 and stored at –70°C until analyzed to measure whole blood nitrite concentrations. Briefly, this solution contains 0.8 mol/L of ferricyanide and 1% Nonidet P-40.39–41
Enzyme Immunoassays of Angiogenic Factors
Serum concentrations of sFLT-1 and sEng were measured with commercially available ELISA kits (R&D Systems) according to the manufacturer’s instructions.
Measurement of Plasma and Whole Blood Nitrite Concentrations
Plasma aliquots were analyzed in triplicate for their nitrite content using an ozone-based chemiluminescence assay, as described previously.42–45 Briefly, 200 µL of plasma samples were injected into a solution of acidified triiodide, purging with nitrogen in-line with a gas-phase chemiluminescence NO analyzer (Sievers Model 280 NO Analyzer). Approximately 8 mL of triiodide solution (2.0 g of potassium iodide and 1.3 g of iodine dissolved in 40 mL of water with 140 mL of acetic acid) were placed in the purge vessel into which plasma samples were injected. The triiodide solution reduced nitrites to NO gas, which was detected by the NO analyzer.
To measure whole blood nitrite concentrations in triplicate, whole blood samples were deproteinated with methanol (1:1) and centrifuged at 14 000g for 3 minutes. Then, 300 µL of supernatant were injected into the solution of acidified triiodide and purged with nitrogen in-line with a gas-phase chemiluminescence NO analyzer, as described above.
Statistical Analysis
Data were reported as the means±SEMs. The clinical and biochemical characteristics of study groups were compared, respectively, by 1-way ANOVA followed by the Dunnett multiple comparisons test, and by the Kruskal-Wallis test followed by the Dunn’s multiple comparison test. The correlations among plasma or whole blood nitrite concentrations and sFLT-1 or sEng concentrations were analyzed using Spearman’s correlation (rs and P values). Statistical analysis was performed with StatView for Windows. A P value of <0.05 was considered the minimum level of statistical significance.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The Table summarizes the clinical characteristics of the 159 subjects enrolled in the present study. There were no significant differences in age, gestational age at sampling, and percentage of primigravida between the hypertensive groups and the control (healthy) group (all P>0.05). However, women with gestational hypertension had higher body mass index than those in the other groups (P<0.05; Table). As expected, higher systolic and diastolic blood pressures were found in women with gestational hypertension or with preeclampsia compared with the control group (both P<0.05; Table). Lower birth weights and gestational ages at delivery were found in the group of preeclamptic women compared with the other groups (P<0.05; Table).
|
Whole blood nitrite levels were significantly lower in the gestational hypertensive subjects and preeclamptic patients (–36% and –58%, respectively; both P<0.05; Figure 1) compared with those found in healthy pregnancies. The plasma nitrite levels were 37% lower in both groups of hypertensive pregnancies compared with the group of normotensive pregnancies (both P<0.05; Figure 1). As expected,34,46–50 we found higher circulating sFLT-1 and sEng concentrations in preeclampsia compared with gestational hypertensive subjects or with healthy pregnancies (both P<0.05; Figure 2).
|
|
To address the possibility that inverse relationships exist between the circulating concentrations of markers of NO formation and sFLT-1 or sEng, we carried out correlation analysis between sFLT-1 or sEng levels and whole blood or plasma nitrite concentrations. Taking into consideration all of the pregnant women, we found significant negative correlations between both antiangiogenic factors and plasma nitrite or whole blood nitrite concentrations (Figure 3; all P<0.05). Interestingly, when we excluded gestational hypertensive women from the analysis, the correlations strengthened even more.
|
), gestational hypertensive (•), and preeclamptic (
) women. The regression line and the 95% CI are plotted. P and Spearman’s correlation (r) values are reported.When we examined whether significant correlations exist between these markers and the severity of preeclampsia, we found that proteinuria correlated significantly with both sFLT-1 and sEng (r=0.490, P=0.002, and r=0.621, P<0.0001, respectively), but not with whole blood or plasma nitrite (both P>0.05). In addition, systolic and diastolic blood pressures correlated significantly with sEng (r=0.5310, P<0.0001, and r=0.353, P=0.008, respectively) but not with other markers (all P>0.05).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This is the first study to measure the circulating nitrite levels in hypertensive disorders of pregnancy. A main novel finding reported here is that patients with preeclampsia or with gestational hypertension have lower whole blood and lower plasma nitrite levels compared with normotensive healthy pregnant women, thus indicating impaired NO formation during hypertensive pregnancies. Moreover, our findings suggest that the circulating concentrations of these markers of NO formation correlate negatively with the increased circulating levels of the antiangiogenic factors sFLT-1 and sEng, a usual finding during preeclampsia.34,46–50
Important changes in maternal cardiovascular hemodynamics take place during normal pregnancy. These modifications include increased blood volume and cardiac output without increases in arterial blood pressure, and 1 of the main reasons for the lack of increase in arterial blood pressure during normal pregnancy is NO-induced systemic vascular dilation.2 Although impaired NO formation has been implicated in the pathogenesis of hypertensive disorders of pregnancy,4–7 no previous study has examined whether these conditions downregulate the circulating levels of relevant markers of NO formation. Because NO is rapidly oxidized to nitrite, recent studies have indicated that measuring plasma nitrite levels may reflect endogenous NO formation. This is because 70% of plasma nitrites derive from NO synthase activity in the endothelium,15 and inhibition of NO synthase activity was associated with corresponding decreases in circulation nitrite concentrations.15,17 The reduced concentrations of both plasma and whole blood nitrite give support to the idea that preeclampsia and gestational hypertension are disorders of pregnancy characterized by impaired NO formation.4–7
The antiangiogenic factors sFLT-1 and sEng have been widely studied in preeclampsia.46,49,51 Our results corroborate previous studies showing strikingly elevated sFLT-1 and sEng levels in preeclampsia compared with healthy pregnancies or with gestational hypertension.34,46–50 These factors probably play a role in the pathophysiology of preeclampsia and have been associated with endothelial dysfunction, which is usually found in this disorder.34,49 The impaired endothelial function could result from sFLT-1–induced antagonism of vascular endothelial growth factor actions,26,27 which include eNOS activation via phosphorylation of Ser-1177 by Akt52 and NO synthesis by endothelial cell.29–31 In fact, our findings showing an inverse correlation between plasma or whole blood nitrite concentrations and sFLT-1 levels are consistent with this suggestion and provide clinical evidence for a pathophysiological mechanism probably playing a role in preeclampsia.
Endoglin is a TGF-β1 and -β3 coreceptor highly expressed in vascular endothelial cells,32 and it may be cleaved in preeclampsia, thus releasing its extracellular domain into the circulation forming sEng. This soluble form of endoglin, in turn, decreases the arterial vasodilatation induced by TGF-β1 and -β3, which is mediated by NO. Indeed, TGF-β receptor activation increases NO formation through increased eNOS expression and activation,53,54 and sEng attenuates eNOS activation by TGF-β by interfering with the Thr495 dephosphorylation of eNOS, thus contributing to decreased NO synthesis.34 The negative correlations that we found between plasma or whole blood nitrite concentrations and sEng support the suggestion that sEng plays a role in the pathogenesis of preeclampsia by decreasing NO formation. Finally, it is possible that increased concentrations of asymmetrical dimethyl arginine (an endogenous NO synthesis inhibitor) contribute to decreased NO signaling in preeclampsia.55
In conclusion, we found clinical evidence for impaired NO formation in patients with preeclampsia or with gestational hypertension. Moreover, the negative correlations that we found between NO markers and sFLT-1 or sEng in preeclamptic patients suggest relevant mechanisms possibly involved in the pathogenesis of this life-threatening condition. These findings may have important therapeutic implications.
Perspectives
In this study, we show clinical evidence for impaired NO formation in patients with preeclampsia or with gestational hypertension. Importantly, the decreased concentrations of markers of NO formation were negatively associated with the circulating levels of relevant antiangiogenic factors produced in the placenta. Although these antiangiogenic factors have been implicated in the pathogenesis of preeclampsia, this is the first study reporting clinical evidence for a possible inhibitory effect caused by these factors on the endogenous formation of NO in patients with preeclampsia. These findings may have important therapeutic implications. Although the cause of upregulation of antiangiogenic factors in preeclampsia remains unknown, it is possible that therapeutic approaches focusing on upregulating NO bioavailability may be useful targets in patients with gestational disorders of pregnancy.
|
Acknowledgments |
|---|
Sources of Funding
This study was funded by the Fundação de Amparo a Pesquisa do Estado de São Paulo and the Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Disclosures
None.
Received April 16, 2008; first decision May 19, 2008; accepted May 29, 2008.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Physiol. 1989; 256: H1060–H1065.[Medline] [Order article via Infotrieve]
2. Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol. 1997; 272: R441–R463.[Medline] [Order article via Infotrieve]
3. Williams DJ, Vallance PJ, Neild GH, Spencer JA, Imms FJ. Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol. 1997; 272: H748–H752.[Medline] [Order article via Infotrieve]
4. Cockell AP, Poston L. Flow-mediated vasodilatation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension. 1997; 30: 247–251.
5. Kublickiene KR, Lindblom B, Kruger K, Nisell H. Preeclampsia: evidence for impaired shear stress-mediated nitric oxide release in uterine circulation. Am J Obstet Gynecol. 2000; 183: 160–166.[Medline] [Order article via Infotrieve]
6. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003; 361: 1511–1517.[CrossRef][Medline] [Order article via Infotrieve]
7. Garcia RG, Celedon J, Sierra-Laguado J, Alarcon MA, Luengas C, Silva F, Arenas-Mantilla M, Lopez-Jaramillo P. Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. Am J Hypertens. 2007; 20: 98–103.[CrossRef][Medline] [Order article via Infotrieve]
8. Aydin S, Benian A, Madazli R, Uludag S, Uzun H, Kaya S. Plasma malondialdehyde, superoxide dismutase, sE-selectin, fibronectin, endothelin-1 and nitric oxide levels in women with preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2004; 113: 21–25.[CrossRef][Medline] [Order article via Infotrieve]
9. D'Anna R, Baviera G, Corrado F, Crisafulli A, Ientile R, Buemi M, Squadrito F. Neurokinin B and nitric oxide plasma levels in pre-eclampsia and isolated intrauterine growth restriction. BJOG. 2004; 111: 1046–1050.[Medline] [Order article via Infotrieve]
10. Schiessl B, Strasburger C, Bidlingmaier M, Mylonas I, Jeschke U, Kainer F, Friese K. Plasma- and urine concentrations of nitrite/nitrate and cyclic Guanosinemonophosphate in intrauterine growth restricted and preeclamptic pregnancies. Arch Gynecol Obstet. 2006; 274: 150–154.[CrossRef][Medline] [Order article via Infotrieve]
11. Yoneyama Y, Suzuki S, Sawa R, Miura A, Doi D, Otsubo Y, Araki T. Plasma nitric oxide levels and the expression of P-selectin on platelets in preeclampsia. Am J Obstet Gynecol. 2002; 187: 676–680.[CrossRef][Medline] [Order article via Infotrieve]
12. Conrad KP, Kerchner LJ, Mosher MD. Plasma and 24-h NO(x) and cGMP during normal pregnancy and preeclampsia in women on a reduced NO(x) diet. Am J Physiol. 1999; 277: F48–F57.[Medline] [Order article via Infotrieve]
13. Norris LA, Higgins JR, Darling MR, Walshe JJ, Bonnar J. Nitric oxide in the uteroplacental, fetoplacental, and peripheral circulations in preeclampsia. Obstet Gynecol. 1999; 93: 958–963.[CrossRef][Medline] [Order article via Infotrieve]
14. Ranta V, Viinikka L, Halmesmaki E, Ylikorkala O. Nitric oxide production with preeclampsia. Obstet Gynecol. 1999; 93: 442–445.[CrossRef][Medline] [Order article via Infotrieve]
15. Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O, Scheeren T, Godecke A, Schrader J, Schulz R, Heusch G, Schaub GA, Bryan NS, Feelisch M, Kelm M. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med. 2003; 35: 790–796.[CrossRef][Medline] [Order article via Infotrieve]
16. Lauer T, Preik M, Rassaf T, Strauer BE, Deussen A, Feelisch M, Kelm M. Plasma nitrite rather than nitrate reflects regional endothelial nitric oxide synthase activity but lacks intrinsic vasodilator action. Proc Natl Acad Sci U S A. 2001; 98: 12814–12819.
17. Kelm M, Preik-Steinhoff H, Preik M, Strauer BE. Serum nitrite sensitively reflects endothelial NO formation in human forearm vasculature: evidence for biochemical assessment of the endothelial L-arginine-NO pathway. Cardiovasc Res. 1999; 41: 765–772.
18. Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, Balzer J, Zotz RB, Scharf RE, Willers R, Schechter AN, Feelisch M, Kelm M. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med. 2006; 40: 295–302.[CrossRef][Medline] [Order article via Infotrieve]
19. Metzger IF, Sertorio JTC, Tanus-Santos JE. Relationship between systemic nitric oxide metabolites and cyclic GMP in healthy male volunteers. Acta Physiol. 2006; 188: 123–127.[CrossRef]
20. McCarthy AL, Woolfson RG, Raju SK, Poston L. Abnormal endothelial cell function of resistance arteries from women with preeclampsia. Am J Obstet Gynecol. 1993; 168: 1323–1330.[Medline] [Order article via Infotrieve]
21. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989; 161: 1200–1204.[Medline] [Order article via Infotrieve]
22. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest. 1997; 99: 2152–2164.[Medline] [Order article via Infotrieve]
23. Hladunewich M, Karumanchi SA, Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol. 2007; 2: 543–549.
24. Baumwell S, Karumanchi SA. Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract. 2007; 106: c72–c81.[CrossRef][Medline] [Order article via Infotrieve]
25. Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res. 2008; 75: 1–8.[CrossRef][Medline] [Order article via Infotrieve]
26. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996; 226: 324–328.[CrossRef][Medline] [Order article via Infotrieve]
27. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct. 2001; 26: 25–35.[CrossRef][Medline] [Order article via Infotrieve]
28. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006; 9: 225–230.[CrossRef][Medline] [Order article via Infotrieve]
29. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem. 1999; 274: 25130–25135.
30. Kroll J, Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun. 1998; 252: 743–746.[CrossRef][Medline] [Order article via Infotrieve]
31. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem. 1999; 274: 33057–33063.
32. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992; 267: 19027–19030.
33. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006; 355: 992–1005.
34. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12: 642–649.[CrossRef][Medline] [Order article via Infotrieve]
35. Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005; 96: 684–692.
36. Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP, Lopez-Novoa JM, Attisano L, Bernabeu C. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol. 2007; 210: 456–468.[CrossRef][Medline] [Order article via Infotrieve]
37. Ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008; 11: 79–89.[CrossRef][Medline] [Order article via Infotrieve]
38. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000; 183: S1–S22.[CrossRef][Medline] [Order article via Infotrieve]
39. Pelletier MM, Kleinbongard P, Ringwood L, Hito R, Hunter CJ, Schechter AN, Gladwin MT, Dejam A. The measurement of blood and plasma nitrite by chemiluminescence: pitfalls and solutions. Free Radic Biol Med. 2006; 41: 541–548.[CrossRef][Medline] [Order article via Infotrieve]
40. Nagassaki S, Sertorio JTC, Metzger IF, Bem AF, Rocha JBT, Tanus-Santos JE. eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite. Free Radic Biol Med. 2006; 41: 1044–1049.[CrossRef][Medline] [Order article via Infotrieve]
41. Dejam A, Hunter CJ, Pelletier MM, Hsu LL, Machado RF, Shiva S, Power GG, Kelm M, Gladwin MT, Schechter AN. Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood. 2005; 106: 734–739.
42. Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA, Tanus-Santos JE. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics. 2005; 15: 565–570.[Medline] [Order article via Infotrieve]
43. Nagassaki S, Metzger IF, Souza-Costa DC, Marroni AS, Uzuelli JA, Tanus-Santos JE. eNOS genotype is without effect on circulating nitrite/nitrate level in healthy male population. Thromb Res. 2005; 115: 375–379.[CrossRef][Medline] [Order article via Infotrieve]
44. Yang BK, Vivas EX, Reiter CD, Gladwin MT. Methodologies for the sensitive and specific measurement of S-nitrosothiols, iron-nitrosyls, and nitrite in biological samples. Free Radic Res. 2003; 37: 1–10.[Medline] [Order article via Infotrieve]
45. Dias-Junior CA, Gladwin MT, Tanus-Santos JE. Low-dose intravenous nitrite improves hemodynamics in a canine model of acute pulmonary thromboembolism. Free Radic Biol Med. 2006; 41: 1764–1770.[CrossRef][Medline] [Order article via Infotrieve]
46. Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. J Clin Endocrinol Metab. 2007; 92: 2672–2679.
47. Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol. 2006; 194: 551–556.[CrossRef][Medline] [Order article via Infotrieve]
48. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol. 2003; 188: 177–182.[CrossRef][Medline] [Order article via Infotrieve]
49. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111: 649–658.[CrossRef][Medline] [Order article via Infotrieve]
50. Levine RJ, Karumanchi SA. Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol. 2005; 48: 372–386.[CrossRef][Medline] [Order article via Infotrieve]
51. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007; 50: 137–142.
52. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS letters. 2000; 477: 258–262.[CrossRef][Medline] [Order article via Infotrieve]
53. Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta 1. Arterioscler Thromb Vasc Biol. 1995; 15: 1255–1261.
54. Saura M, Zaragoza C, Cao W, Bao C, Rodriguez-Puyol M, Rodriguez-Puyol D, Lowenstein CJ. Smad2 mediates transforming growth factor-beta induction of endothelial nitric oxide synthase expression. Circ Res. 2002; 91: 806–813.
55. Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand. 1998; 77: 808–813.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  V. C. Sandrim, A. C. T. Palei, R. C. Cavalli, F. M. Araujo, E. S. Ramos, G. Duarte, and J. E. Tanus-Santos Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension Mol. Hum. Reprod., February 1, 2009; 15(2): 115 - 120. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||